Cleo Diagnostics Begins Ovarian Cancer Screening Test Development
Key points
- Prototype development of multi-marker screening blood test is underway
- Targeting a $150B global addressable market for early-stage ovarian cancer detection
- Screening test development runs parallel to FDA submission for pre-surgical test in H1 CY2027
Full summary
Cleo Diagnostics Ltd has initiated the prototype development of its multi-biomarker screening blood test, targeting a $150 billion global market for early-stage ovarian cancer detection in asymptomatic women. This development represents the next phase of the company's strategic growth, leveraging existing technology and clinical datasets. The screening test will be developed alongside the company's pre-surgical triage test, which is on track for FDA submission in the first half of the 2027 calendar year. Cleo Diagnostics aims to finalize the screening test panel architecture by the end of the 2026 calendar year, with initial proof-of-concept data expected early in the next quarter.
Outlook
Cleo Diagnostics aims to finalize the screening test panel architecture by the end of the 2026 calendar year.
Summary generated by a large language model. Please interpret with care.